WO2001060350A3 - Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation - Google Patents

Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation Download PDF

Info

Publication number
WO2001060350A3
WO2001060350A3 PCT/US2001/004917 US0104917W WO0160350A3 WO 2001060350 A3 WO2001060350 A3 WO 2001060350A3 US 0104917 W US0104917 W US 0104917W WO 0160350 A3 WO0160350 A3 WO 0160350A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine receptor
identifying
cell proliferation
receptor antagonists
mammalian cell
Prior art date
Application number
PCT/US2001/004917
Other languages
French (fr)
Other versions
WO2001060350A2 (en
Inventor
Luiz Belardinelli
Maria B Grant
Original Assignee
Cv Therapeutics Inc
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc, Univ Florida filed Critical Cv Therapeutics Inc
Priority to CA002400206A priority Critical patent/CA2400206A1/en
Priority to JP2001559448A priority patent/JP2003535818A/en
Priority to IL15116001A priority patent/IL151160A0/en
Priority to AU2001238342A priority patent/AU2001238342A1/en
Priority to BR0108454-2A priority patent/BR0108454A/en
Priority to EP01910770A priority patent/EP1255550A2/en
Priority to MXPA02007761A priority patent/MXPA02007761A/en
Publication of WO2001060350A2 publication Critical patent/WO2001060350A2/en
Publication of WO2001060350A3 publication Critical patent/WO2001060350A3/en
Priority to NO20023878A priority patent/NO20023878D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

This invention concerns methods for identifying A2B adenosine receptor agonists and antagonists as well as methods for using A2B adenosine receptor antagonists to treat cell proliferation orders mediated by the A2B adenosine receptor.
PCT/US2001/004917 2000-02-17 2001-02-16 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation WO2001060350A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002400206A CA2400206A1 (en) 2000-02-17 2001-02-16 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
JP2001559448A JP2003535818A (en) 2000-02-17 2001-02-16 Methods of identifying and using A2B adenosine receptor antagonists that mediate mammalian cell proliferation
IL15116001A IL151160A0 (en) 2000-02-17 2001-02-16 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
AU2001238342A AU2001238342A1 (en) 2000-02-17 2001-02-16 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
BR0108454-2A BR0108454A (en) 2000-02-17 2001-02-16 Methods for identification and use of adenosine receptor antagonists a (2b) papa to mediate cell proliferation in mammals
EP01910770A EP1255550A2 (en) 2000-02-17 2001-02-16 Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
MXPA02007761A MXPA02007761A (en) 2000-02-17 2001-02-16 Method for identifying and using a2b.
NO20023878A NO20023878D0 (en) 2000-02-17 2002-08-15 Method of Identifying and Using A2B Adenosine Receptor Antagonists to Mediate Mammalian Cell Proliferation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18314100P 2000-02-17 2000-02-17
US60/183,141 2000-02-17

Publications (2)

Publication Number Publication Date
WO2001060350A2 WO2001060350A2 (en) 2001-08-23
WO2001060350A3 true WO2001060350A3 (en) 2002-04-04

Family

ID=22671613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004917 WO2001060350A2 (en) 2000-02-17 2001-02-16 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation

Country Status (13)

Country Link
US (1) US6894021B2 (en)
EP (1) EP1255550A2 (en)
JP (1) JP2003535818A (en)
KR (1) KR20030031466A (en)
CN (1) CN1420775A (en)
AU (1) AU2001238342A1 (en)
BR (1) BR0108454A (en)
CA (1) CA2400206A1 (en)
IL (1) IL151160A0 (en)
MX (1) MXPA02007761A (en)
NO (1) NO20023878D0 (en)
WO (1) WO2001060350A2 (en)
ZA (1) ZA200206582B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
RU2357969C2 (en) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи New substituted 8-heteroarylxantines and based pharmaceutical composition
JP4929173B2 (en) * 2004-09-01 2012-05-09 ギリアード・パロ・アルト・インコーポレイテッド Method of wound healing using an A2B adenosine receptor antagonist
JP2008516969A (en) 2004-10-15 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Methods of preventing and treating airway remodeling and lung inflammation using A2B adenosine receptor antagonists
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
ES2274712B1 (en) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. NEW IMIDAZOPIRIDINE DERIVATIVES.
US20070208042A1 (en) 2006-03-03 2007-09-06 Sherwood Services Ag Method of using vasoconstrictive agents during energy-based tissue therapy
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CA2657973A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP5460690B2 (en) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド Heterocyclic compounds as adenosine receptor antagonists
CN107407897B (en) * 2015-03-30 2019-05-03 住友理工株式会社 Electronic photographing device electroconductive component

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO1999042093A2 (en) * 1998-02-24 1999-08-26 University Of Virginia Antagonists of a2b human adenosine receptors
WO1999063938A2 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
WO2000051621A1 (en) * 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
WO2000073307A2 (en) * 1999-06-01 2000-12-07 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
US6440933B1 (en) * 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO1999042093A2 (en) * 1998-02-24 1999-08-26 University Of Virginia Antagonists of a2b human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
WO1999063938A2 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
WO2000051621A1 (en) * 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
WO2000073307A2 (en) * 1999-06-01 2000-12-07 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRANT M B ET AL: "Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells.", CIRCULATION RESEARCH, (1999 OCT 15) 85 (8) 699-706, XP001038638 *

Also Published As

Publication number Publication date
ZA200206582B (en) 2003-04-09
IL151160A0 (en) 2003-04-10
EP1255550A2 (en) 2002-11-13
CN1420775A (en) 2003-05-28
JP2003535818A (en) 2003-12-02
US6894021B2 (en) 2005-05-17
NO20023878L (en) 2002-08-15
KR20030031466A (en) 2003-04-21
BR0108454A (en) 2003-04-01
CA2400206A1 (en) 2001-08-23
US20020002142A1 (en) 2002-01-03
MXPA02007761A (en) 2002-10-11
WO2001060350A2 (en) 2001-08-23
AU2001238342A1 (en) 2001-08-27
NO20023878D0 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
WO2001060350A3 (en) Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
WO2004000102A3 (en) Method for predicting response to epidermal growth factor receptor-directed therapy
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2003008623A3 (en) Methylation analysis using nicking agents
WO2003008622A3 (en) Exponential nucleic acid amplification using nicking endonucleases
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2006071891A3 (en) Evaluating central nervous system
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
AU2001238665A1 (en) Method of identifying partial agonists of the a2a receptor
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
HK1092137A1 (en) Xanthine derivatives as a2b adenosine receptor antagonists
TW200723247A (en) Removing time delays in signal paths
AU2002312471A1 (en) Method for distributing large files to multiple recipients
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
WO2005116252A8 (en) Methods for evaluating ribonucleotide sequences
WO2009014612A3 (en) Modified nucleotides, methods for making and using same
WO2006043047A3 (en) A spatial aggregator system for providing information
WO2003066809A3 (en) Mismatch endonucleases and methods of use
MY129445A (en) Compositions for treating inflammatory response
SG156664A1 (en) Metal ion-containing cmp composition and method for using the same
AU2002308628A1 (en) Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
AU2002347859A1 (en) System, method, and apparatus for submitting genetic samples and receiving genetic testing results anonymously
AU2003303869A1 (en) Methods for nucleic acid analysis
WO2003087051A3 (en) Methods for identifying allosteric sites
WO2004067750A3 (en) Xenorhabdus tc proteins and genes for pest control

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 520625

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 151160

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007761

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002/01985

Country of ref document: TR

Ref document number: 2400206

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001238342

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020027010597

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002/06582

Country of ref document: ZA

Ref document number: 018051502

Country of ref document: CN

Ref document number: 200206582

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 559448

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001910770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910770

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027010597

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001910770

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020027010597

Country of ref document: KR